Screener
Arcus Biosciences RCUS Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's return on equity?
- Arcus Biosciences (RCUS) reported return on equity of -90.8% in Q2 2026.
- How has Arcus Biosciences's return on equity changed year-over-year?
- Arcus Biosciences's return on equity decreased by 80.4% year-over-year, from -50.3% to -90.8%.
- What is the long-term trend for Arcus Biosciences's return on equity?
- Over 5 years (2020 to 2025), Arcus Biosciences's return on equity has grown at a 11.4% compound annual growth rate (CAGR), from -36.9% to -63.3%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Arcus Biosciences's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude